OBJECTIVES: The aim of this study was to test the hypothesis that trimethoprim/sulfamethoxazole selects for integron-positive and multidrug-resistant Enterobacteriaceae in the intestinal flora. METHODS: During 1 year of follow-up, antibiotic susceptibility and the presence of integrons were determined in faecal Enterobacteriaceae isolated from 99 children with chronic active otitis media, randomly assigned to treatment with trimethoprim/sulfamethoxazole or placebo (http://www.clinicaltrials.gov/; trial registration number NCT00189098). RESULTS: At 6 and 12 weeks of follow-up, 32 (91%) and 24 (67%) children in the trimethoprim/sulfamethoxazole group carried trimethoprim/sulfamethoxazole-resistant Enterobacteriaceae versus 10 (21%) and 8 (17%) children in the placebo group [rate differences (RDs): 70 (95% CI: 55; 85) and 50 (95% CI: 31; 69)], respectively. Multiresistance also increased during trimethoprim/sulfamethoxazole treatment. At 6 weeks of follow-up, the integron prevalence was 26 (79%) in the trimethoprim/sulfamethoxazole group and 10 (22%) in the placebo group [RD: 57 (95% CI: 39; 75)]. After 12 weeks the integron prevalence, and after 1 year the susceptibility levels, had returned to baseline values. CONCLUSIONS: Initially, trimethoprim/sulfamethoxazole usage was strongly associated with the appearance of integron-positive (multi)drug-resistant Enterobacteriaceae in the intestinal flora. After prolonged exposure to trimethoprim/sulfamethoxazole, however, this population of Enterobacteriaceae was substituted by a population with non-integron-associated resistance mechanisms. After trimethoprim/sulfamethoxazole was discontinued, susceptibility rates to all antibiotics returned to baseline levels.
RCT Entities:
OBJECTIVES: The aim of this study was to test the hypothesis that trimethoprim/sulfamethoxazole selects for integron-positive and multidrug-resistant Enterobacteriaceae in the intestinal flora. METHODS: During 1 year of follow-up, antibiotic susceptibility and the presence of integrons were determined in faecal Enterobacteriaceae isolated from 99 children with chronic active otitis media, randomly assigned to treatment with trimethoprim/sulfamethoxazole or placebo (http://www.clinicaltrials.gov/; trial registration number NCT00189098). RESULTS: At 6 and 12 weeks of follow-up, 32 (91%) and 24 (67%) children in the trimethoprim/sulfamethoxazole group carried trimethoprim/sulfamethoxazole-resistant Enterobacteriaceae versus 10 (21%) and 8 (17%) children in the placebo group [rate differences (RDs): 70 (95% CI: 55; 85) and 50 (95% CI: 31; 69)], respectively. Multiresistance also increased during trimethoprim/sulfamethoxazole treatment. At 6 weeks of follow-up, the integron prevalence was 26 (79%) in the trimethoprim/sulfamethoxazole group and 10 (22%) in the placebo group [RD: 57 (95% CI: 39; 75)]. After 12 weeks the integron prevalence, and after 1 year the susceptibility levels, had returned to baseline values. CONCLUSIONS: Initially, trimethoprim/sulfamethoxazole usage was strongly associated with the appearance of integron-positive (multi)drug-resistant Enterobacteriaceae in the intestinal flora. After prolonged exposure to trimethoprim/sulfamethoxazole, however, this population of Enterobacteriaceae was substituted by a population with non-integron-associated resistance mechanisms. After trimethoprim/sulfamethoxazole was discontinued, susceptibility rates to all antibiotics returned to baseline levels.
Authors: Lee-Yee Chong; Karen Head; Katie E Webster; Jessica Dew; Peter Richmond; Tom Snelling; Mahmood F Bhutta; Anne Gm Schilder; Martin J Burton; Christopher G Brennan-Jones Journal: Cochrane Database Syst Rev Date: 2021-02-04
Authors: Jameson B Wood; Donald B Smith; Errol H Baker; Stephen M Brecher; Kalpana Gupta Journal: Antimicrob Agents Chemother Date: 2012-08-20 Impact factor: 5.191
Authors: Sameer J Patel; André P Oliveira; Juyan Julia Zhou; Luis Alba; E Yoko Furuya; Scott A Weisenberg; Haomiao Jia; Sarah A Clock; Christine J Kubin; Stephen G Jenkins; Audrey N Schuetz; Maryam Behta; Phyllis Della-Latta; Susan Whittier; Kyu Rhee; Lisa Saiman Journal: Am J Infect Control Date: 2014-04-13 Impact factor: 2.918
Authors: Le Thi Minh Vien; Ngo Ngoc Quang Minh; Tang Chi Thuong; Huynh Duy Khuong; Tran Vu Thieu Nga; Corinne Thompson; James I Campbell; Menno de Jong; Jeremy J Farrar; Constance Schultsz; H Rogier van Doorn; Stephen Baker Journal: PLoS One Date: 2012-08-24 Impact factor: 3.240
Authors: Lee-Yee Chong; Karen Head; Katie E Webster; Jessica Daw; Peter Richmond; Tom Snelling; Mahmood F Bhutta; Anne Gm Schilder; Martin J Burton; Christopher G Brennan-Jones Journal: Cochrane Database Syst Rev Date: 2021-02-09
Authors: Christopher G Brennan-Jones; Karen Head; Lee-Yee Chong; Martin J Burton; Anne Gm Schilder; Mahmood F Bhutta Journal: Cochrane Database Syst Rev Date: 2020-01-02
Authors: Karen Head; Lee-Yee Chong; Mahmood F Bhutta; Peter S Morris; Shyan Vijayasekaran; Martin J Burton; Anne Gm Schilder; Christopher G Brennan-Jones Journal: Cochrane Database Syst Rev Date: 2020-01-06